Literature DB >> 21918520

Endogenic and iatrogenic diabetes mellitus in drug-naïve schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm.

Dan Cohen, Marc De Hert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21918520      PMCID： PMC3176580          DOI： 10.1038/npp.2011.94

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  4 in total

1.  Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.

Authors:  Jimmi Nielsen; Søren Skadhede; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-06-02       Impact factor: 7.853

Review 2.  Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Authors:  Christine Rummel-Kluge; Katja Komossa; Sandra Schwarz; Heike Hunger; Franziska Schmid; Claudia Asenjo Lobos; Werner Kissling; John M Davis; Stefan Leucht
Journal:  Schizophr Res       Date:  2010-08-07       Impact factor: 4.939

Review 3.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

4.  The Danish National Diabetes Register: trends in incidence, prevalence and mortality.

Authors:  B Carstensen; J K Kristensen; P Ottosen; K Borch-Johnsen
Journal:  Diabetologia       Date:  2008-09-25       Impact factor: 10.122
  4 in total
  8 in total

1.  Aminotransferase levels as a prospective predictor for the development of metabolic syndrome in patients with schizophrenia.

Authors:  Eun Young Kim; Se Hyun Kim; Nam Young Lee; Jin Sang Yoon; Chul Eung Kim; Yong Sik Kim; Yong Min Ahn
Journal:  Psychopharmacology (Berl)       Date:  2014-05-13       Impact factor: 4.530

Review 2.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

3.  Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis.

Authors:  Suat Kucukgoncu; Urska Kosir; Elton Zhou; Erin Sullivan; Vinod H Srihari; Cenk Tek
Journal:  Early Interv Psychiatry       Date:  2018-10-02       Impact factor: 2.732

Review 4.  Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.

Authors:  Alex J Mitchell; Davy Vancampfort; Amber De Herdt; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

5.  Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis.

Authors:  Debra L Foley; Andrew Mackinnon; Vera A Morgan; Gerald F Watts; John J McGrath; David J Castle; Anna Waterreus; Cherrie A Galletly
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

6.  The Psychology of Food Cravings in Patients With First-Episode Psychosis.

Authors:  Young-Hyuk Kim; Seunghyong Ryu; Hee-Jung Nam; Mina Kim; Min Jhon; Ju-Yeon Lee; Jae-Min Kim; Min Ho Shin; Young-Chul Chung; Sung-Wan Kim
Journal:  Front Psychiatry       Date:  2020-12-11       Impact factor: 4.157

7.  Genetic underpinnings of left superior temporal gyrus thickness in patients with schizophrenia.

Authors:  Rick P F Wolthusen; Johanna Hass; Esther Walton; Jessica A Turner; Veit Rössner; Scott R Sponheim; Beng-Choon Ho; Daphne J Holt; Randy L Gollub; Vince Calhoun; Stefan Ehrlich
Journal:  World J Biol Psychiatry       Date:  2015-08-07       Impact factor: 4.132

8.  Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender.

Authors:  Debra L Foley; Andrew Mackinnon; Gerald F Watts; Jonathan E Shaw; Dianna J Magliano; David J Castle; John J McGrath; Anna Waterreus; Vera A Morgan; Cherrie A Galletly
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.